{
    "body": "Are there any HCV replication inhibitors available?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23791700", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23466233", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23688081", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23629709", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24154738", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23896953", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23453230", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23896281", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24165192", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23745769", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23230455", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23431163", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23384816", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23454058", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23440335", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21694902", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21331152"
    ], 
    "triples": [
        {
            "p": "http://data.linkedct.org/resource/linkedct/intervention_type", 
            "s": "http://data.linkedct.org/resource/intervention/24334", 
            "o": "Drug"
        }, 
        {
            "p": "http://www.w3.org/2000/01/rdf-schema#label", 
            "s": "http://data.linkedct.org/resource/intervention/24334", 
            "o": "Intervention #24334 (Drug:HCV polymerase inhibitor pro-drug)"
        }, 
        {
            "p": "http://data.linkedct.org/resource/linkedct/intervention_name", 
            "s": "http://data.linkedct.org/resource/intervention/24334", 
            "o": "HCV polymerase inhibitor pro-drug"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A10759582", 
            "o": "Drug"
        }, 
        {
            "p": "http://data.linkedct.org/resource/linkedct/intervention_type", 
            "s": "http://data.linkedct.org/resource/intervention/23449", 
            "o": "Drug"
        }, 
        {
            "p": "http://www.w3.org/2000/01/rdf-schema#label", 
            "s": "http://data.linkedct.org/resource/intervention/23449", 
            "o": "Intervention #23449 (Drug:HCV polymerase inhibitor pro-drug)"
        }, 
        {
            "p": "http://data.linkedct.org/resource/linkedct/intervention_name", 
            "s": "http://data.linkedct.org/resource/intervention/23449", 
            "o": "HCV polymerase inhibitor pro-drug"
        }, 
        {
            "p": "http://data.linkedct.org/resource/linkedct/intervention_type", 
            "s": "http://data.linkedct.org/resource/intervention/26936", 
            "o": "Drug"
        }, 
        {
            "p": "http://data.linkedct.org/resource/linkedct/intervention_name", 
            "s": "http://data.linkedct.org/resource/intervention/26936", 
            "o": "HCV polymerase inhibitor pro-drug"
        }, 
        {
            "p": "http://www.w3.org/2000/01/rdf-schema#label", 
            "s": "http://data.linkedct.org/resource/intervention/26936", 
            "o": "Intervention #26936 (Drug:HCV polymerase inhibitor pro-drug)"
        }, 
        {
            "p": "http://data.linkedct.org/resource/linkedct/intervention_type", 
            "s": "http://data.linkedct.org/resource/intervention/28754", 
            "o": "Drug"
        }, 
        {
            "p": "http://www.w3.org/2000/01/rdf-schema#label", 
            "s": "http://data.linkedct.org/resource/intervention/28754", 
            "o": "Intervention #28754 (Drug:HCV polymerase inhibitor pro-drug)"
        }, 
        {
            "p": "http://data.linkedct.org/resource/linkedct/intervention_name", 
            "s": "http://data.linkedct.org/resource/intervention/28754", 
            "o": "HCV polymerase inhibitor pro-drug"
        }, 
        {
            "p": "http://data.linkedct.org/resource/linkedct/intervention_type", 
            "s": "http://data.linkedct.org/resource/intervention/24333", 
            "o": "Drug"
        }, 
        {
            "p": "http://www.w3.org/2000/01/rdf-schema#label", 
            "s": "http://data.linkedct.org/resource/intervention/24333", 
            "o": "Intervention #24333 (Drug:HCV polymerase inhibitor pro-drug)"
        }, 
        {
            "p": "http://data.linkedct.org/resource/linkedct/intervention_name", 
            "s": "http://data.linkedct.org/resource/intervention/24333", 
            "o": "HCV polymerase inhibitor pro-drug"
        }
    ], 
    "ideal_answer": [
        "Chronic hepatitis C virus (HCV) infection is a worldwide health problem causing serious complications, such as liver cirrhosis and hepatoma. Small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) have been reported to suppress gene expression significantly. HCV seems a suitable candidate for targets of siRNAs, as HCV is a positive single-strand RNA virus and replicates in the cytoplasm.  Based on results, nowadays there are few HCV replication inhibitors such as GS-563253, PSI-6130, NA-808, BMS-790052, GS-9132 and BMS-788329."
    ], 
    "exact_answer": "yes", 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014779", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004364"
    ], 
    "type": "yesno", 
    "id": "53353927d6d3ac6a34000043", 
    "snippets": [
        {
            "offsetInBeginSection": 778, 
            "offsetInEndSection": 925, 
            "text": "We report here the discovery of the first small-molecule HCV infectivity inhibitor, GS-563253, also called HCV infectivity inhibitor 1 (HCV II-1). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24165192", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 140, 
            "text": "Resistance to mericitabine (prodrug of HCV NS5B polymerase inhibitor PSI-6130) is rare and conferred by the NS5B S282T mutation.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24154738", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 525, 
            "offsetInEndSection": 616, 
            "text": "We tested the ability of NA808 to inhibit SPT's enzymatic activity in FLR3-1 replicon cells", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23791700", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1488, 
            "offsetInEndSection": 1631, 
            "text": "The SPT inhibitor NA808 prevents replication of HCV genotypes 1a, 1b, 2a, 3a, and 4a in cultured hepatocytes and in mice with humanized livers.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23791700", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 123, 
            "offsetInEndSection": 263, 
            "text": "Vaniprevir (phase III clinical trials) and MK-5172 (phase II clinical trials) are two potent antiviral compounds that target NS3/4A protease", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23745769", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 4, 
            "offsetInEndSection": 200, 
            "text": "treatment for hepatitis C virus (HCV) infection has been significantly improved with the approval of the first two HCV NS3/4A protease inhibitors, telaprevir (Incivek) and boceprevir (Victrelis). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23688081", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 717, 
            "offsetInEndSection": 1271, 
            "text": "Combination therapy with telaprevir and BMS-788329 (NS5A inhibitor) reduced serum HCV RNA to undetectable levels. The presence of an NS3-V36A telaprevir resistance mutation resulted in poor response to telaprevir monotherapy but showed significant HCV reduction when telaprevir was combined with BMS-788329. However, a BMS-788329-resistant strain emerged at low frequency. Infection with a BMS-788329-resistant NS5A-L31V mutation rapidly resulted in gain of an additional NS5A-Y93A mutation that conferred telaprevir resistance during combination therapy", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23896953", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 130, 
            "offsetInEndSection": 240, 
            "text": "HCV NS5A replication complex inhibitors, exemplified by Daclatasvir (BMS-790052), represent a new class of DAA", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23896281", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 169, 
            "offsetInEndSection": 265, 
            "text": "ACH-806 (or GS-9132) is a novel, small-molecule inhibitor specific for hepatitis C virus (HCV). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629709", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 160, 
            "offsetInEndSection": 329, 
            "text": "Telaprevir and boceprevir are the first two protease inhibitor (PI) DAAs to be approved for combination therapy with pegylated interferon (PEG-IFN) and ribavirin (RBV). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23453230", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 13, 
            "offsetInEndSection": 130, 
            "text": "symmetrical bidentate structure of the NS5A inhibitor BMS-790052, a series of new monodentate molecules were designed", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23466233", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1040, 
            "offsetInEndSection": 1204, 
            "text": "In vitro, boceprevir is more active than telaprevir against the HCV G3 NS3/4A enzyme in cell-based and biochemical assays and against G3 isolates in replicon assays", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23454058", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 351, 
            "offsetInEndSection": 577, 
            "text": "Alisporivir is the most advanced host-targeting antiviral in clinical development. Alisporivir blocks HCV replication by neutralizing the peptidyl-prolyl isomerase activity of the abundant host cytosolic protein, cyclophilin A", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23440335", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 102, 
            "offsetInEndSection": 264, 
            "text": "Interestingly, the NS5A inhibitor daclatasvir (BMS-790052) caused a decrease in serum HCV RNA levels by about two orders of magnitude within 6 h of administration", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23431163", 
            "endSection": "abstract"
        }
    ]
}